BRK-B vs NXP
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
NXP exhibits severe valuation misalignment, trading at $14.16 despite a Graham Number of $6.95 and an Intrinsic Value of $1.05. While the Piotroski F-Score of 5/9 indicates stable financial health, this is overshadowed by a catastrophic payout ratio of 418%, signaling an unsustainable dividend. Negative earnings growth (-11.2% YoY) combined with an astronomical P/E ratio of 94.40 suggests the asset is significantly overpriced relative to its fundamental earning power. The technical trend is completely bearish (0/100), reinforcing a negative outlook.
Compare Another Pair
Related Comparisons
BRK-B vs NXP: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and Nuveen Select Tax-Free Income Portfolio (NXP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.